Allergan PLC. (AGN) Shares Sold by Bridges Investment Counsel Inc.

Bridges Investment Counsel Inc. trimmed its position in shares of Allergan PLC. (NYSE:AGN) by 74.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,522 shares of the company’s stock after selling 16,386 shares during the period. Bridges Investment Counsel Inc.’s holdings in Allergan PLC. were worth $1,132,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in AGN. Waldron LP acquired a new stake in shares of Allergan PLC. during the 1st quarter worth $348,000. BP PLC increased its holdings in shares of Allergan PLC. by 45.3% during the 1st quarter. BP PLC now owns 54,500 shares of the company’s stock worth $13,027,000 after buying an additional 17,000 shares during the last quarter. Marietta Wealth Management LLC increased its holdings in shares of Allergan PLC. by 313.8% during the 1st quarter. Marietta Wealth Management LLC now owns 5,375 shares of the company’s stock worth $1,284,000 after buying an additional 4,076 shares during the last quarter. South State Corp increased its holdings in shares of Allergan PLC. by 76.5% during the 1st quarter. South State Corp now owns 13,902 shares of the company’s stock worth $3,322,000 after buying an additional 6,024 shares during the last quarter. Finally, Iridian Asset Management LLC CT increased its holdings in shares of Allergan PLC. by 141.3% during the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after buying an additional 751,848 shares during the last quarter. Institutional investors and hedge funds own 81.94% of the company’s stock.

Shares of Allergan PLC. (AGN) traded down 0.52% during trading on Friday, hitting $188.28. 4,755,555 shares of the stock traded hands. Allergan PLC. has a one year low of $182.80 and a one year high of $256.80. The firm has a 50 day moving average price of $211.30 and a 200-day moving average price of $230.36. The company has a market cap of $62.94 billion, a PE ratio of 5.74 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. Analysts anticipate that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.

Allergan PLC. declared that its board has initiated a stock repurchase program on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

AGN has been the subject of several recent research reports. UBS AG reiterated an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Wells Fargo & Company reiterated an “outperform” rating and issued a $258.00 price target on shares of Allergan PLC. in a report on Wednesday. Deutsche Bank AG set a $251.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Tuesday, October 17th. Finally, Mizuho downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $193.00 price target for the company. in a report on Thursday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $252.39.

ILLEGAL ACTIVITY NOTICE: This report was originally published by T

Several other hedge funds have also recently added to or reduced their stakes in AGN. Waldron LP acquired a new stake in shares of Allergan PLC. during the 1st quarter worth $348,000. BP PLC increased its holdings in shares of Allergan PLC. by 45.3% during the 1st quarter. BP PLC now owns 54,500 shares of the company’s stock worth $13,027,000 after buying an additional 17,000 shares during the last quarter. Marietta Wealth Management LLC increased its holdings in shares of Allergan PLC. by 313.8% during the 1st quarter. Marietta Wealth Management LLC now owns 5,375 shares of the company’s stock worth $1,284,000 after buying an additional 4,076 shares during the last quarter. South State Corp increased its holdings in shares of Allergan PLC. by 76.5% during the 1st quarter. South State Corp now owns 13,902 shares of the company’s stock worth $3,322,000 after buying an additional 6,024 shares during the last quarter. Finally, Iridian Asset Management LLC CT increased its holdings in shares of Allergan PLC. by 141.3% during the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after buying an additional 751,848 shares during the last quarter. Institutional investors and hedge funds own 81.94% of the company’s stock.

Shares of Allergan PLC. (AGN) traded down 0.52% during trading on Friday, hitting $188.28. 4,755,555 shares of the stock traded hands. Allergan PLC. has a one year low of $182.80 and a one year high of $256.80. The firm has a 50 day moving average price of $211.30 and a 200-day moving average price of $230.36. The company has a market cap of $62.94 billion, a PE ratio of 5.74 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. Analysts anticipate that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.

Allergan PLC. declared that its board has initiated a stock repurchase program on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

AGN has been the subject of several recent research reports. UBS AG reiterated an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Wells Fargo & Company reiterated an “outperform” rating and issued a $258.00 price target on shares of Allergan PLC. in a report on Wednesday. Deutsche Bank AG set a $251.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Tuesday, October 17th. Finally, Mizuho downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $193.00 price target for the company. in a report on Thursday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $252.39.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/22/allergan-plc-agn-shares-sold-by-bridges-investment-counsel-inc.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply